Cochrane Abstracts
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Rifamycins (rifampicin, Rifabutin and Rifapentine) Compared to Isoniazid for Preventing Tuberculosis in HIV-negative People at Risk of Active TB: Cochrane Systematic Review." Cochrane Abstracts, John Wiley & Sons, Inc, 2026. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433809/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review.
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review. Cochrane Abstracts. John Wiley & Sons, Inc; 2026. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433809/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review. Accessed January 24, 2026.
Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review. (2026). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433809/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review
Rifamycins (rifampicin, Rifabutin and Rifapentine) Compared to Isoniazid for Preventing Tuberculosis in HIV-negative People at Risk of Active TB: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2026. [cited 2026 January 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433809/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB: Cochrane systematic review
ID - 433809
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433809/all/Rifamycins__rifampicin__rifabutin_and_rifapentine__compared_to_isoniazid_for_preventing_tuberculosis_in_HIV_negative_people_at_risk_of_active_TB:_Cochrane_systematic_review
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
